New cancer drug combo tested in early human trial
Disease control
Completed
This early-phase trial tested an experimental drug called IOS-1002, given alone or with the immunotherapy pembrolizumab, in 47 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. Research…
Phase: PHASE1 • Sponsor: ImmunOs Therapeutics AG • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC